• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic.

作者信息

Glasziou P P, Tikkinen Kao

机构信息

Institute for Evidence Based Healthcare, Bond University, Gold Coast, Australia.

Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

出版信息

J R Soc Med. 2021 Sep;114(9):443-446. doi: 10.1177/01410768211041245.

DOI:10.1177/01410768211041245
PMID:34533083
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8451011/
Abstract
摘要

相似文献

1
The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic.RECOVERY试验平台：疫情期间治疗评估发展与实施过程中的一个里程碑。
J R Soc Med. 2021 Sep;114(9):443-446. doi: 10.1177/01410768211041245.
2
COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results.新冠病毒疾病（COVID-19）临床试验：RECOVERY试验结果的伦理与科学影响
Basic Clin Pharmacol Toxicol. 2020 Dec;127(6):445-447. doi: 10.1111/bcpt.13489. Epub 2020 Sep 30.
3
Public Health Research During the COVID-19 Epidemic.新冠疫情期间的公共卫生研究
Asia Pac J Public Health. 2021 May;33(4):333-334. doi: 10.1177/10105395211012844. Epub 2021 May 3.
4
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.AGILE-ACCORD：一项旨在确定多种候选药物治疗 COVID-19 的最佳剂量、安全性和疗效的随机、多中心、无缝、适应性 I/II 期平台研究：一项随机平台试验研究方案的结构化总结。
Trials. 2020 Jun 19;21(1):544. doi: 10.1186/s13063-020-04473-1.
5
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
6
Evaluation of new or repurposed treatments for COVID-19: protocol for the phase Ib/IIa DEFINE trial platform.COVID-19 新疗法或再利用疗法的评估：DEFINE 试验平台的 Ib/IIa 期研究方案。
BMJ Open. 2021 Dec 15;11(12):e054442. doi: 10.1136/bmjopen-2021-054442.
7
Compounded research challenges amid the COVID-19 pandemic.在新冠疫情期间，研究面临着复杂的挑战。
Anaesth Crit Care Pain Med. 2020 Dec;39(6):689-690. doi: 10.1016/j.accpm.2020.09.002. Epub 2020 Sep 16.
8
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.
9
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.PROTECT 试验：羟氯喹对比观察支持用于预防或 COVID-19 早期治疗的一项集群随机对照研究：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 31;21(1):689. doi: 10.1186/s13063-020-04527-4.
10
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.巴瑞替尼治疗 COVID-19 住院患者的疗效（RECOVERY 研究）：一项随机、对照、开放标签、平台试验及更新的荟萃分析。
Lancet. 2022 Jul 30;400(10349):359-368. doi: 10.1016/S0140-6736(22)01109-6.

引用本文的文献

1
Lessons from the PROTECT-CH COVID-19 platform trial in care homes.来自护理院PROTECT-CH COVID-19平台试验的经验教训。
Health Technol Assess. 2025 Apr 9:1-26. doi: 10.3310/MTRS8833.
2
The impact of heterogeneity on the analysis of platform trials with normally distributed outcomes.平台试验中异质性对正态分布结局分析的影响。
BMC Med Res Methodol. 2024 Jul 30;24(1):163. doi: 10.1186/s12874-024-02293-4.
3
Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial.COVID-19 感染住院后接受瑞德西韦治疗的效果：来自随机 SOLIDARITY 芬兰试验的结果。
Nat Commun. 2022 Oct 18;13(1):6152. doi: 10.1038/s41467-022-33825-5.
4
The true meaning of DICE: don't ignore chance effects.DICE的真正含义：不要忽视机遇效应。
J R Soc Med. 2021 Dec;114(12):575-577. doi: 10.1177/01410768211064102.
5
Why RECOVERY is a milestone in medical research.为何“康复”是医学研究中的一个里程碑。
J R Soc Med. 2021 Sep;114(9):419-420. doi: 10.1177/01410768211043972.

本文引用的文献

1
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
2
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 患者住院期间使用阿司匹林（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Jan 8;399(10320):143-151. doi: 10.1016/S0140-6736(21)01825-0. Epub 2021 Nov 17.
3
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 住院患者中应用秋水仙碱（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet Respir Med. 2021 Dec;9(12):1419-1426. doi: 10.1016/S2213-2600(21)00435-5. Epub 2021 Oct 18.
4
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.COVID-19 患者住院期间的恢复期血浆治疗（RECOVERY）：一项随机对照、开放标签、平台试验。
Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14.
5
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
6
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
7
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.洛匹那韦利托那韦在因 COVID-19 住院的患者中的应用（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4. Epub 2020 Oct 5.
8
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
9
COVID-19 clinical trials: learning from exceptions in the research chaos.COVID-19临床试验：从研究混乱中的例外情况中学习。
Nat Med. 2020 Nov;26(11):1671-1672. doi: 10.1038/s41591-020-1077-z.
10
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.